Bayer: FDA approves Vitrakvi for rare types of cancer
(CercleFinance.com) - The US Food and Drug Administration has approved Vitrakvi for the treatment of cancers that have an NTRK gene fusion, a rare driver of cancer.
TRK fusions affect both children and adults and can be found in many types of solid tumors, including lung, thyroid, melanoma, colon, soft tissue sarcoma, and infantile fibrosarcoma.
In clinical trials, Vitrakvi demonstrated an overall response rate (ORR) - the proportion of patients whose tumor is destroyed or significantly reduced - of 75%, including a 22% complete response (CR) rate.
Vitrakvi is developed by Bayer and US-based drugmaker Loxo Oncology.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
TRK fusions affect both children and adults and can be found in many types of solid tumors, including lung, thyroid, melanoma, colon, soft tissue sarcoma, and infantile fibrosarcoma.
In clinical trials, Vitrakvi demonstrated an overall response rate (ORR) - the proportion of patients whose tumor is destroyed or significantly reduced - of 75%, including a 22% complete response (CR) rate.
Vitrakvi is developed by Bayer and US-based drugmaker Loxo Oncology.
Copyright (c) 2018 CercleFinance.com. All rights reserved.